Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90
Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.
You may also be interested in...
Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.
Roche is preparing to launch HER2 positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) in Europe following approval from the European Commission.
If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.